Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial.
Philip J ThompsonGerard J CrinerMark T DransfieldDavid M G HalpinMeiLan K HanDavid A LipsonGhassan J MaghzalFernando J MartinezDawn MidwinterDave SinghLee TombsRobert A WisePublished in: Respirology (Carlton, Vic.) (2022)
FF/UMEC/VI had a favourable benefit: risk profile versus dual therapies irrespective of CMH status. The presence of CMH did not influence treatment response or exacerbations, lung function and/or health status. However, CMH did generate differences when dual therapies were compared and the impact of CMH should be considered in future trial design.